Tüdőrák: nyitott vizsgálatok itt: Mexikó

41 nyitott vizsgálatnak van helyszíne itt: Mexikó. Regiszteradat; hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Kísérleti kezelés · 3. fázis · Amgen
Actualidad Basada en la Investigación del Cáncer, Guadalajara · Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara · Health Pharma Professional Research SA de CV, Mexico City · Oncare, Monterrey · Hospital Universitario Dr. Jose Eleuterio González, Monterrey · Centro de Investigacion Clinica de Oaxaca, Oaxaca City
Regiszter frissítve: 2026-11-06
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Hoffmann-La Roche
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara · ARKE Estudios Clínicos S.A. de C.V., Mexico City
Regiszter frissítve: 2026-11-05
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Kísérleti kezelés · 3. fázis · Pfizer
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara · Instituto Nacional de Cancerologia, Mexico City · Centro de Investigacion Clinica de Oaxaca, Oaxaca City · Clinica Integral Internacional de Oncolgia S. de R.L. de C.V ú Oncocenter, Puebla City
Regiszter frissítve: 2026-11-05
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Monterrey · Puebla City · Querétaro · Saltillo · Tijuana · Zapopan
Regiszter frissítve: 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Eli Lilly and Company
PanAmerican Clinical Research - Guadalajara, Guadalajara · Renati Innovation, Guadalajara · Actualidad Basada en la Investigación del Cáncer, Guadalajara · CIO - Centro de Inmuno-Oncología de Occidente, Guadalajara · Health Pharma Querétaro, Juriquilla · Preparaciones Oncológicas S.C., León · Higiea Oncologia, Mexico City · Health Pharma Professional Research S.A. de C.V., Mexico City · Avix Investigación Clínica, S.C., Monterrey · Hospital Universitario Dr. Jose Eleuterio González, Monterrey · Centro de Investigacion Clinica de Oaxaca, Oaxaca City · Clinica Integral Internacional de Oncología, Puebla City · Oncare - Unidad Valle, San Pedro Garza García · Arké SMO S.A de C.V, Veracruz
Regiszter frissítve: 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Kísérleti kezelés · 3. fázis · Bayer
Instituto Nacional de Cancerologia, Mexico City · Oncare Viaducto Nápoles, Mexico City · Hospital Universitrio Dr. José Eleuterio González. Servicio de Oncologia, Monterrey · Oncologia Integral Satelite, Naucalpan · Clinica Integral Internacional de Oncologia S. de R.L. de C.V., Puebla City · ONCARE Treatment Center, San Pedro Garza García
Regiszter frissítve: 2026-11-04
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
CIO - Centro de Inmuno-Oncología de Occidente (Site 0715), Guadalajara · Higiea Oncologia (Site 0721), Mexico City · Axis Heilsa S. de R.L. de C.V. (Site 0719), Monterrey · Oaxaca Site Management Organization S.C. (Site 0718), Oaxaca City · Clinica Integral Internacional de Oncología (Site 0714), Puebla City · Centro de Atención e Investigación Cardiovascular del Potosí (Site 0713), San Luis Potosí City
Regiszter frissítve: 2026-11-03
NCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Kísérleti kezelés · 3. fázis · Boehringer Ingelheim
Centro Oncologico Internacional, Jalisco · Instituto Nacional de Cancerologia, México · Centro Oncologico Personalizado, México · Centro de Infusion Profesional Integral (CIPI), Mexico City · Centro Medico Zambrano Hellion, Monterrey
Regiszter frissítve: 2026-11-02
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Kísérleti kezelés · 2/3. fázis · Mirati Therapeutics Inc.
Cancer Treatment Clinic and Clinical Trials, Guadalajara · Local Institution - Unk070, Guadalajara · Arke SMO S.A. de C.V., Mexico City · Local Institution - Unk049, Mexico City · Local Institution - Unk034, Mexico City · Local Institution - Unk026, Monterrey · AVIX Investigacion Clinica, Monterrey · Local Institution - Unk037, Monterrey
Regiszter frissítve: 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Kísérleti kezelés · 3. fázis · AbbVie
O.P.D. Hospital Civil de Guadalajara /ID# 238488, Guadalajara · Centro de Investigacion Clínica Chapultepec SA de CV /ID# 231928, Morelia · Clinical Research & Oncology Oaxaca /ID# 231883, Oaxaca City
Regiszter frissítve: 2026-10-29
NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Kísérleti kezelés · 1/2. fázis · Pfizer
INCAN, Mexico City · Hospital MAC Periferico Sur, Mexico City · COI Centro Oncologico Internacional S.A.P.I. de C.V., Mexico City · Hospital Universitario Dr. Jose Eleuterio González, Monterrey · Hospital Reforma, Oaxaca City · Oaxaca Site Management Organization, Oaxaca City
Regiszter frissítve: 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Kísérleti kezelés · 3. fázis · Boehringer Ingelheim
Centro Medico Nacional de Occidente/ Centro De Investigacion Biomedica De Occidente, Guadalajara, Jalisco · Centro Oncologico Personalizado, México · Instituto Nacional de Cancerologia, México · Health Pharma Professional Research S.A. de C.V., Mexico City · Centro Medico Zambrano Hellion, Monterrey · Hospital Universitario Dr Jose Eleuterio Gonzalez, Nuevo León · Centro Oncologico Estatal ISSEMyM "Dr. Jose Luis Barrera Franco", Toluca
Regiszter frissítve: 2026-10-28
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Kísérleti kezelés · 3. fázis · Mirati Therapeutics Inc.
Hospital Civil Fray Antonio Alcalde, Guadalajara · Gefarma (Atrys), Mexico City · Axis Heilsa S. de R.L. de C.V., Monterrey · Grupo Ollin Care, Pachuca · Unidad Médica Onco-hematológica, Puebla City · Centro de Infusion E Investigacion Oncologia de Saltillo S.C., Saltillo · FAICIC S. de R.L. de C.V., Veracruz
Regiszter frissítve: 2026-10-27
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Instituto Nacional de Cancerologia. (Site 0608), México · Arké SMO S.A. de C.V. (Site 0602), Mexico City · Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia (Site 0600), Monterrey · Oaxaca Site Management Organization S.C. (Site 0603), Oaxaca City
Regiszter frissítve: 2026-10-26
NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Grupo Médico ASSET SC (Site 0811), Benito Juárez · Scientia Investigacion Clinica S.C. (Site 0804), Chihuahua City · CANCER TREAMTENT CLINIC AND CLINICAL TRIALS SA DE CV (Site 0801), Guadalajara · Instituto Nacional de Cancerologia. (Site 0808), Mexico City · Laboratorio de Patología Clínica del Hospital Universitario "Dr. José Eleuterio González" (Site 0800), Monterrey · Centro de Investigacion Clinica de Oaxaca (Site 0813), Oaxaca City · Clinica Integral Internacional de Oncología (Site 0812), Puebla City
Regiszter frissítve: 2026-10-26
NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Cancer Treamtent Clinic and Clinical Trials Sa de Cv, Guadalajara · Arké SMO S.A. de C.V., México · Hospital H+ Queretaro, Querétaro · Centro Potosino de Investigación Médica, San Luis Potosí City
Regiszter frissítve: 2026-10-23
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Kísérleti kezelés · 3. fázis · Daiichi Sankyo
Clinstile, S.A. de C.V., Mexico City
Regiszter frissítve: 2026-10-23
NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Kísérleti kezelés · 2/3. fázis · Bristol-Myers Squibb
Chihuahua City · Guadalajara · Cancer Treamtent Clinic and Clinical Trials Sa de Cv, Guadalajara · Mexico City · Mexico City · CENEIT Oncologicos, Mexico City · Monterrey · Oaxaca City · Puebla City · Puebla City · Querétaro · Tijuana · Zapopan
Regiszter frissítve: 2026-10-23
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Guadalajara · Mexico City · Mexico City · Mexico City · Monterrey · Oaxaca City · Puebla City · Querétaro · Zapopan
Regiszter frissítve: 2026-10-23
NCT07099898
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Kísérleti kezelés · 3. fázis · GlaxoSmithKline
Guadajalara · Mexico City · San Pedro Garza García
Regiszter frissítve: 2026-10-20
NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Kísérleti kezelés · 3. fázis · Merck Sharp & Dohme LLC
Unidad de Mastologia Avanzada de Chihuahua S.A de C.V (Site 0504), Chihuahua City · Mediadvance Clinical (Site 0502), Chihuahua City · CIO - Centro de Inmuno-Oncología de Occidente (Site 0506), Guadalajara · Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Servicio de Oncología (Site 0508), Monterrey · Oaxaca Site Management Organization S.C. (Site 0507), Oaxaca City · Centro de Investigacion Clinica de Oaxaca (Site 0509), Oaxaca City
Regiszter frissítve: 2026-10-15
NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Kísérleti kezelés · 3. fázis · Bristol-Myers Squibb
Guadalajara · Puebla City
Regiszter frissítve: 2026-10-13
NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Kísérleti kezelés · 3. fázis · Taiho Oncology, Inc.
Preparaciones Oncológicas S.C., León · Centro Oncológico Alianza XXI, Mexico City · Clínica Integral Internacional de Oncología S de RL de CV, Mirador
Regiszter frissítve: 2026-10-13
NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Kísérleti kezelés · 2/3. fázis · Bristol-Myers Squibb
Chihuahua City · Mexico City · Mexico City · Oaxaca City
Regiszter frissítve: 2026-10-09
NCT06765109
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Kísérleti kezelés · 3. fázis · Nuvalent Inc.
Instituto Nacional de Cancerologia, Mexico City · Health Pharma Professional Research S.A. de C.V., Mexico City · Centro Oncológico Personalizado, Mexico City · Hospital Universitario Dr. Jose Eleuterio González, Monterrey · Centro de Investigacion Clinica Chapultepec S.A. de C.V., Morelia · Oncologia Integral Satelite S. A. de C. V., Naucalpan
Regiszter frissítve: 2026-09-30

Minden vizsgálat (Tüdőrák) és a térkép

Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.

Hibát jelzek